Pharmaceutical Market Size, Trends & Industry Forecast 2032

Pharmaceutical Market Size & Overview:

The Global Pharmaceutical Market Size was valued at USD 1598 Billion in 2023 and is projected to hit USD 2845.3 Billion by 2032, growing at a CAGR of 6.6% over the forecast period 2024-2032.

Pharmaceutical Market Revenue Analysis

To get more information on Pharmaceutical Market - Request Free Sample Report

The Pharmaceutical Market Report 2023-2024 provides essential statistical insights and trends affecting the pharmaceutical industry. It includes disease incidence and prevalence and trends for prescriptions by region and the volume of drugs produced and consumed. The report also examines healthcare spending on pharmaceuticals, describing government, private, and out-of-pocket outlays. It also points out trends in the growing field of biologics and biosimilars and discusses the changing regulatory and compliance landscape impacting drug approvals and pricing. This report serves as a valuable resource for understanding market dynamics and future opportunities in the pharmaceutical sector. The pharmaceutical market is witnessing significant growth currently due to the growing prevalence of chronic disease, the aging population, and increasing healthcare expenditure. Indian Government aims to increase healthcare expenditure from 1.7% to 1.8% of the country's GDP to 2.5% by 2025. India is the largest supplier of generic medicines in the world with a 20% global market share by volume and came in the third position in the production of pharmaceutical products globally by volume.

Pharmaceutical Market Dynamics

Drivers

Increased adoption of sustainable and energy-efficient practices in pharmaceutical manufacturing to reduce environmental impact.

To reduce its carbon footprint, the pharmaceutical industry is increasingly embracing sustainable and energy-efficient practices. For example, in 2024 Piramal Pharma Limited saw a 29% rise in renewable energy consumption. For instance, in 2024, Piramal Pharma Limited reported a 29% increase in renewable energy consumption. Using 2022 as the base year, Piramal Pharma Limited aims to reduce absolute Scope 1 and 2 greenhouse gas emissions by 42% and Scope 3 emissions by 25% by fiscal year 2030. Glenmark Pharmaceuticals, for instance, reduced its carbon emission intensity by 10% over the last three years, through energy efficiency measures and renewable energy source integration, with 6% of its energy now being sourced sustainably.

AstraZeneca is also working toward sustainability on the product side, with its Breztri inhaler in the pipeline using a propellant with 99.9% less global warming potential than the hydrofluorocarbons traditionally used, aiming to lower its annual greenhouse gas emissions by 1.3 million tons. These projects mirror a widespread industry change toward environmental consciousness, motivated by regulatory pressures and a sense of public health. Pharmaceutical companies are also working to reduce their carbon footprints and promote sustainability by adopting renewable energy, improving energy efficiency, and creating greener products.

Restraints:

Stringent and evolving regulatory frameworks across different regions, leading to increased compliance costs and complexities.

The pharmaceutical industry faces significant restraint due to stringent and evolving regulatory frameworks. To facilitate drug safety, efficacy, and quality these regulations differ substantially across regions rendering a complex picture for the pharmaceutical companies working globally. Over 65% of pharmaceutical firms reported increased compliance costs as a result of changing regulatory guidelines in key markets like the US, EU, and China according to a recent 2024 International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) report.

In addition, the emergence of new treatment modalities such as gene editing and personalized medicine has created new challenges and necessitated a more rigorous assessment of their clinical utility. For example, the European Medicines Agency (EMA) noted a 40% increase in regulatory reviews of advanced therapy medicinal products (ATMPs) from the previous year, a sign of the increasing complexity of compliance obligations. All these trends towards increased regulation, require larger investments in legal practitioners, good quality control systems, and clinical studies, putting even more strain on resources, particularly for smaller biotech companies.

Opportunities:

Integration of artificial intelligence (AI) and big data analytics in drug discovery and development, enhancing efficiency and enabling personalized medicine approaches.

AI and big data analytics are systematically transforming drug discovery and development processes and offering enormous potential to improve efficiency and insight in pharmaceutical research. It typically takes more than 10 years and costs over $2 billion to develop a new drug. This complexity is one of the reasons why AI can speed this process up, as it allows for faster and more accurate identification of potential drug candidates based on enormous sets of data. AI models can predict the behaviour of molecules and optimize lead compounds, which will considerably reduce the costs and timeline such experiments typically incur within laboratories. A notable example is the AI-designed drug DSP-1181, developed by Exscientia, which reached clinical trials in under a year, significantly faster than traditional timelines. Beyond new drug discovery, AI-enabled platforms have accelerated complex disease treatments; Regeneron's Evinacumab is a key example of an AI-discovered drug that directly targets rare complex genetic disorders by targeting the ANGPTL3 protein. With the adoption of AI and big data analytics by more pharmaceutical companies, the industry will be able to bring new therapies to readers more effectively, allowing for more unmet medical needs to be addressed and better patient outcomes.

Challenges:

High research and development (R&D) costs and lengthy drug approval processes, often exceeding $2 billion and taking over a decade, hindering the timely introduction of new therapies.

The pharma sector is currently having a challenge with high R&D costs and longer timelines for drug approvals. Top companies in 2024 (Roche & Johnson & Johnson) are estimated to spend nearly USD 9.9 billion on research & development. Despite these substantial investments, the pathway to bringing a new drug to market remains arduous. In the US, the Food and Drug Administration (FDA) has a goal under the Prescription Drug User Fee Act (PDUFA) to review New Drug Applications within 10 months with a 6-month goal for priority reviews. However, these target dates are not always achieved, resulting in delays. In Australia, for example, patients wait an average of 466 days from the time the Therapeutic Goods Administration approves the drug to its availability on the Pharmaceutical Benefits Scheme. With the soaring R&D costs, long timelines to the market also present a huge challenge to the timely introduction of new therapies, affecting patient access to better therapeutics.

Pharmaceutical Market Segmentation Insights

By Molecule Type

Conventional drugs (small molecules) held the leading revenue share of 54% of the market in 2023. Their prevalence is due in large part to established manufacturing processes and relatively predictable pharmacokinetics, along with oral bioavailability. According to estimates, there are about 3,000 drug companies and over 10,000 manufacturing units in the Indian pharmaceutical industry, which is keenly focused on conventional medicine. The government's push for self-reliance in manufacturing APIs (Active Pharmaceutical Ingredients) which are primarily used in conventional drugs has also strengthened this segment. To encourage local manufacturing of critical Active Pharmaceutical Ingredients (APIs) and cut down on import dependence, the Indian government launched the Production Linked Incentive (PLI) scheme. This effort is likely to contribute to the growth of the conventional drugs segment.

By Product

In 2023, the branded segment held the largest revenue share of 66% in the pharmaceutical market. Their reign can be attributed to multiple elements such as brand awareness, perceived quality, and patient trust. Government initiatives aimed at fostering innovation and R&D in the pharmaceutical space have notably catalyzed the growth of branded products in India. As per experts in the industry, the allocation of 10% or more of the National Research Fund to life sciences can further encourage the establishment of branded pharmaceutical products. Moreover, the government aims to increase healthcare spending to 2.5% of GDP by 2025 and this creates an opportunity for an increase in consumption of branded pharmaceuticals. Branded products are also perceived by healthcare providers and patients to be of better quality than generics, which additionally bolsters their market dominance.

By Type

In 2023, the prescription segment accounted for the largest revenue share of 88% in the pharmaceutical market. This presents a large share that is mainly driven by chronic diseases, the increasing aging population, and growing healthcare expenditure. As India has made great strides with government schemes in targeting healthcare access, the prescription segment experienced significant growth in response. The availability of prescription drugs has increased in India due to health insurance coverage for more than 500 million Indians through the Ayushman Bharat scheme. With the increase in prescriptions, the natural market has also grown as a direct result. In addition, the Indian pharmaceutical industry has a solid emphasis on R&D as companies earmark around 8.4% of their sales for research, leading to the generation of new prescription drugs. The government's target to increase this allocation to match the global average of 10-11% is expected to further drive innovation in prescription medications.

By Disease

Cancer held a market share of 17% in 2023 and led the market. Such a high share can be credited to the growing prevalence of cancer not only globally but also in India. The Indian Council of Medical Research (ICMR) projects India's cancer cases to rise from 1.39 million in 2020 to 1.57 million in 2025. Since then, the Indian government has made some efforts to cope with the increasing burden of cancers. In addition, the NPCDCS (National Programme for Prevention and Control of Cancer, Diabetes, Cardiovascular Diseases and Stroke) programme supports early detection, management and referral of cancer cases. Additionally, the focus of the Indian pharmaceutical industry has gradually shifted towards Oncology research and development. Top Indian pharmaceutical companies are now focusing on specialty portfolios from cancer treatments. The government's thrust towards enhancing healthcare spending and developing R&D in the pharmaceutical sector is likely to propel cancer therapeutics' development further.

By Route of Administration

In 2023, the oral route led the market by accounting for 57% of revenue. Several factors, such as patient preference, ease of administration, and cost-effectiveness have contributed to this dominance. The strength of the Indian pharmaceutical industry lies in the manufacture of generic medicines, particularly in the oral dosage form. The ensuing push from the government to promote API manufacturing in the country, which is used mainly in oral formulations, has additionally helped this segment strengthen. The PLI scheme will help in cutting down reliance on imports and encourage local manufacturers to produce critical active pharmaceutical ingredients (APIs) used in oral medicines. India's strength in making inexpensive oral formulations is in sync with the governments reach out to enrich affordable health care for the huge population.

By Formulation

In 2023 tablets accounted for the largest market share at 27%. Several factors contribute to this dominance, which include ease of manufacturing, cost-effective solutions, and patient compliance. The Indian pharmaceutical industry has a solid manufacturing base, particularly for tablet formulation. The government push to bolster the domestic setup of pharma manufacturing capabilities has added to the already buoyant tablet segment. The Production Linked Incentive (PLI) scheme, which aims to boost domestic production of critical APIs and formulations, is expected to drive growth in tablet manufacturing.

By End Market

The hospitals segment held the largest revenue share of 53% in the pharmaceuticals market in 2023. This success is due to the increasingly large number of hospital admissions, the increasing prevalence of chronic diseases, and the development of healthcare infrastructure in India. Government focus on the healthcare infrastructure in India has also been a significant driver for the growth of the hospital segment. The PMSSY seeks to address regional imbalances in the availability of affordable and reliable tertiary healthcare services. The creation and upgradation of government medical colleges and new AIIMS (All India Institute of Medical Sciences) institutes through this initiative have also increased the demand for pharmaceuticals in hospital settings Additionally, the government initiative to increase healthcare expenditure to reach 2.5% of GDP by 2025 will inject impetus for further growth in the hospital segment. Moreover, the widening of health insurance coverage and access to hospital treatment under schemes such as Ayushman Bharat have expanded hospital pharmaceutical consumption.

Pharmaceutical Market Regional Analysis

In 2023, North America was the largest revenue contributor to the global pharmaceutical market, with a revenue share of 45.0%. These factors include healthcare development, healthcare expenditure, high health conditions, and a high level of the pharmaceutical industry. The United States, in particular, leads the global pharmaceutical market, generating almost half of the world's pharmaceutical revenues. During the forecast period, the Asia Pacific region is projected to grow at a faster CAGR. Rapid growth is due to factors such as increasing healthcare expenditure, growing population, rising prevalence of chronic diseases, and increasing healthcare infrastructure in countries like India and China. The Asia Pacific region has been a key growth area, especially for India. India is the third largest in terms of volume of production of pharmaceuticals 14th in terms of value. With a 20% global supply share by volume, India today as the world's largest supplier of generic medicine has a stronghold on the global pharmaceutical market. This growth can be credited to initiatives taken by the Indian government to boost the pharmaceutical sector. These include allowing 100% FDI under automatic approval for greenfield investments and up to 74% for brownfield investments.

Get Customized Report as per Your Business Requirement - Enquiry Now

Key Players in Pharmaceutical Industry

Key Service Providers/Manufacturers

Pfizer Inc. (Comirnaty, Ibrance)
Johnson & Johnson (Stelara, Darzalex)
Roche Holding AG (Herceptin, Avastin)
Novartis AG (Cosentyx, Kisqali)
Merck & Co., Inc. (Keytruda, Gardasil 9)
Sanofi (Dupixent, Lantus)
AstraZeneca (Tagrisso, Farxiga)
GlaxoSmithKline plc (GSK) (Shingrix, Trelegy Ellipta)
Eli Lilly and Company (Mounjaro, Trulicity)
Bristol-Myers Squibb (BMS) (Opdivo, Eliquis)
AbbVie Inc. (Humira, Rinvoq)
Moderna, Inc. (Spikevax, mRNA-1273.222)
Gilead Sciences, Inc. (Biktarvy, Veklury)
Bayer AG (Xarelto, Eylea)
Takeda Pharmaceutical Company (Entyvio, Ninlaro)
Amgen Inc. (Repatha, Prolia)
Biogen Inc. (Spinraza, Aduhelm)
Regeneron Pharmaceuticals, Inc. (Dupixent, Eylea)
Boehringer Ingelheim (Jardiance, Ofev)
Teva Pharmaceuticals (Austedo, Ajovy)

Recent Developments

On February 14, 2025, Zydus Lifesciences' subsidiary partnered with Zhuhai Beihai Biotech to market Beizray, an albumin-solubilized docetaxel injection, in the US. Under the agreement, Zhuhai will handle manufacturing, while Zydus will oversee commercialization, targeting cancers such as breast and non-small cell lung cancer.
In May 2024, Siren Biotechnology partnered up with Catalent, Inc. for the manufacturing of AAV gene therapies for potential cancer treatment.

**Pharmaceutical Market Report Scope:**
Report Attributes	Details
Market Size in 2023	USD 1598 Billion
Market Size by 2032	USD 2845.3 Billion
CAGR	CAGR of 6.6% From 2024 to 2032
Base Year	2023
Forecast Period	2024-2032
Historical Data	2020-2022
Report Scope & Coverage	Market Size, Segments Analysis, Competitive Landscape, Regional Analysis, DROC & SWOT Analysis, Forecast Outlook
Key Segments	• By Pharmaceutical Molecule Type • By Pharmaceutical Product • By Pharmaceutical Type • By Pharmaceutical Disease • By Pharmaceutical Route of Administration • By Pharmaceutical Formulation • By Pharmaceutical End Market
Regional Analysis/Coverage	North America (US, Canada, Mexico), Europe (Eastern Europe [Poland, Romania, Hungary, Turkey, Rest of Eastern Europe] Western Europe] Germany, France, UK, Italy, Spain, Netherlands, Switzerland, Austria, Rest of Western Europe]), Asia Pacific (China, India, Japan, South Korea, Vietnam, Singapore, Australia, Rest of Asia Pacific), Middle East & Africa (Middle East [UAE, Egypt, Saudi Arabia, Qatar, Rest of Middle East], Africa [Nigeria, South Africa, Rest of Africa], Latin America (Brazil, Argentina, Colombia, Rest of Latin America)
Company Profiles	Pfizer Inc., Johnson & Johnson, Roche Holding AG, Novartis AG, Merck & Co., Inc., Sanofi, AstraZeneca, GlaxoSmithKline plc (GSK), Eli Lilly and Company, Bristol-Myers Squibb (BMS), AbbVie Inc., Moderna, Inc., Gilead Sciences, Inc., Bayer AG, Takeda Pharmaceutical Company, Amgen Inc., Biogen Inc., Regeneron Pharmaceuticals, Inc., Boehringer Ingelheim, Teva Pharmaceuticals.

Frequently Asked Questions

What is the projected market size of the Pharmaceutical Market by 2032?

Ans. The projected market size for the Pharmaceutical Market is USD 2845.3 Billion by 2032.

Which region dominated the Pharmaceutical Market in 2023?

Ans: The North American region dominated the Pharmaceutical Market in 2023.

What is the CAGR of the Pharmaceutical Market?

Ans. The CAGR of the Pharmaceutical Market is 6.6% During the forecast period of 2024-2032.

Which Molecule Type segment dominated the Pharmaceutical Market?

Ans: The Conventional drugs segment dominated the Pharmaceutical Market.

What are the opportunities for the Pharmaceutical Market?

Ans:

Integration of artificial intelligence (AI) and big data analytics in drug discovery and development, enhancing efficiency and enabling personalized medicine approaches.

An accurate research report requires proper strategizing as well as implementation. There are multiple factors involved in the completion of good and accurate research report and selecting the best methodology to compete the research is the toughest part. Since the research reports we provide play a crucial role in any company’s decision-making process, therefore we at SNS Insider always believe that we should choose the best method which gives us results closer to reality. This allows us to reach at a stage wherein we can provide our clients best and accurate investment to output ratio.

Each report that we prepare takes a timeframe of 350-400 business hours for production. Starting from the selection of titles through a couple of in-depth brain storming session to the final QC process before uploading our titles on our website we dedicate around 350 working hours. The titles are selected based on their current market cap and the foreseen CAGR and growth.

The 5 steps process:

Step 1: Secondary Research:

Secondary Research or Desk Research is as the name suggests is a research process wherein, we collect data through the readily available information. In this process we use various paid and unpaid databases which our team has access to and gather data through the same. This includes examining of listed companies’ annual reports, Journals, SEC filling etc. Apart from this our team has access to various associations across the globe across different industries. Lastly, we have exchange relationships with various university as well as individual libraries.

Secondary Research

Step 2: Primary Research

When we talk about primary research, it is a type of study in which the researchers collect relevant data samples directly, rather than relying on previously collected data. This type of research is focused on gaining content specific facts that can be sued to solve specific problems. Since the collected data is fresh and first hand therefore it makes the study more accurate and genuine.

We at SNS Insider have divided Primary Research into 2 parts.

Part 1 wherein we interview the KOLs of major players as well as the upcoming ones across various geographic regions. This allows us to have their view over the market scenario and acts as an important tool to come closer to the accurate market numbers. As many as 45 paid and unpaid primary interviews are taken from both the demand and supply side of the industry to make sure we land at an accurate judgement and analysis of the market.

This step involves the triangulation of data wherein our team analyses the interview transcripts, online survey responses and observation of on filed participants. The below mentioned chart should give a better understanding of the part 1 of the primary interview.

Primary Research

Part 2: In this part of primary research the data collected via secondary research and the part 1 of the primary research is validated with the interviews from individual consultants and subject matter experts.

Consultants are those set of people who have at least 12 years of experience and expertise within the industry whereas Subject Matter Experts are those with at least 15 years of experience behind their back within the same space. The data with the help of two main processes i.e., FGDs (Focused Group Discussions) and IDs (Individual Discussions). This gives us a 3^rd party nonbiased primary view of the market scenario making it a more dependable one while collation of the data pointers.

Step 3: Data Bank Validation

Once all the information is collected via primary and secondary sources, we run that information for data validation. At our intelligence centre our research heads track a lot of information related to the market which includes the quarterly reports, the daily stock prices, and other relevant information. Our data bank server gets updated every fortnight and that is how the information which we collected using our primary and secondary information is revalidated in real time.

Data Bank Validation

Step 4: QA/QC Process

After all the data collection and validation our team does a final level of quality check and quality assurance to get rid of any unwanted or undesired mistakes. This might include but not limited to getting rid of the any typos, duplication of numbers or missing of any important information. The people involved in this process include technical content writers, research heads and graphics people. Once this process is completed the title gets uploader on our platform for our clients to read it.

Step 5: Final QC/QA Process:

This is the last process and comes when the client has ordered the study. In this process a final QA/QC is done before the study is emailed to the client. Since we believe in giving our clients a good experience of our research studies, therefore, to make sure that we do not lack at our end in any way humanly possible we do a final round of quality check and then dispatch the study to the client.

Key Market Segments:

By Pharmaceutical Molecule Type

Biologics & Biosimilars (Large Molecules)
- Monoclonal Antibodies
- Vaccines
- Cell & Gene Therapy
- Others
Conventional Drugs (Small Molecules)

By Pharmaceutical Product

Branded
Generics

By Pharmaceutical Type

Prescription
OTC

By Pharmaceutical Disease

Cardiovascular diseases
Cancer
Diabetes
Infectious diseases
Neurological disorders
Respiratory diseases
Autoimmune diseases
Mental health disorders
Gastrointestinal disorders
Women’s health Diseases
Genetic and rare genetic diseases
Dermatological conditions
Obesity
Renal diseases
Liver conditions
Hematological disorders
Eye conditions
Infertility conditions
Endocrine disorders
Allergies
Others

By Pharmaceutical Route of Administration

Oral
Topical
Parenteral
Intravenous
Intramuscular
Inhalations
Other

By Pharmaceutical Formulation

Tablets
Capsules
Injectable
Sprays
Suspensions
Powders
Other Formulations

By Pharmaceutical End Market

Hospitals
Clinics
Others

Request for Segment Customization as per your Business Requirement: Segment Customization Request

Regional Coverage:

North America

US
Canada
Mexico

Europe

Eastern Europe
- Poland
- Romania
- Hungary
- Turkey
- Rest of Eastern Europe
Western Europe
- Germany
- France
- UK
- Italy
- Spain
- Netherlands
- Switzerland
- Austria
- Rest of Western Europe

Asia Pacific

China
India
Japan
South Korea
Vietnam
Singapore
Australia
Rest of Asia Pacific

Middle East & Africa

Middle East
- UAE
- Egypt
- Saudi Arabia
- Qatar
- Rest of Middle East
Africa
- Nigeria
- South Africa
- Rest of Africa

Latin America

Brazil
Argentina
Colombia
Rest of Latin America

Request for Country Level Research Report: Country Level Customization Request

Available Customization

With the given market data, SNS Insider offers customization as per the company’s specific needs. The following customization options are available for the report:

Detailed Volume Analysis
Criss-Cross segment analysis (e.g. Product X Application)
Competitive Product Benchmarking
Geographic Analysis
Additional countries in any of the regions
Customized Data Representation
Detailed analysis and profiling of additional market players

Single User License 3350
~~5000~~ (33% Discount)
Enterprise User License 6450
~~8950~~ (40% Discount)
Excel Datasheet 2350
~~3050~~ (23% Discount)

Buy Now Request An Analyst Call

Pharmaceutical Market Size & Overview:

Pharmaceutical Market Dynamics

Pharmaceutical Market Segmentation Insights

Pharmaceutical Market Regional Analysis

Key Players in Pharmaceutical Industry

Pharmaceutical Market Report Scope:

Frequently Asked Questions

Table of Contents:

Key Market Segments:

Medical Writing Market

mHealth Market

Healthcare Asset Management Market

Tissue Diagnostics Market

Cleanroom technologies Market

Ecotoxicological Studies Market

Start a Conversation

Call Now

Call Now

Mail Us

Related Link

Quick Links

Payment Options

Pharmaceutical Market Size & Overview:

Pharmaceutical Market Dynamics

Pharmaceutical Market Segmentation Insights

Pharmaceutical Market Regional Analysis

Key Players in Pharmaceutical Industry

Pharmaceutical Market Report Scope:

Frequently Asked Questions

Table of Contents:

Key Market Segments:

Related Reports :

Medical Writing Market

mHealth Market

Healthcare Asset Management Market

Tissue Diagnostics Market

Cleanroom technologies Market

Ecotoxicological Studies Market

Subscribe Now to Our Weekly Newsletter!

Select any four category

Start a Conversation

Call Now

Call Now

Mail Us

Related Link

Quick Links

Payment Options

Cookies Consent